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Abstract
Purpose Prostate-specific antigen (PSA)-based screening
for prostate cancer (PC) has dramatically increased early
diagnosis. Current imaging techniques are not optimal to
stage early PC adequately. A promising alternative to PC
imaging is peptide-based scintigraphy using radiolabelled
bombesin (BN) analogues that bind to gastrin-releasing
peptide receptors (GRPR) being overexpressed in PC.
When labelled to appropriate radionuclides BN targeting
of GRPRs may also provide applications for peptide
radionuclide receptor therapy (PRRT). Assessment studies
under identical experimental conditions allowing a reliable
comparison of the potential of such analogues are lacking.
This study was performed to evaluate and directly compare
five promising radiolabelled BN analogues for their targeting
efficacy for PC under standardised conditions.
Methods The BN agonists [111In]DOTA-PESIN, [111In]
AMBA, [111In]MP2346 and [111In]MP2653 and one
antagonist [99mTc]Demobesin-1 were evaluated in
GRPR-overexpressing human PC-3 tumour-bearing mice
to determine peptide stability in vivo, biodistribution and
GRPR targeting potential by animal SPECT/CT imaging
and ex vivo autoradiography.
Results HPLC analysis of blood showed intact Demobesin-
1 at 5 and 15 min after injection (64.1±1.6% and 41.0±
01%, respectively) being much less for the other com-
pounds. AMBA, the second most stable analogue, showed
36.1±2.7% and 9.8±1.1% intact peptide after 5 and
15 min. PC-3 tumour uptake at 1 h was comparable for
Demobesin-1, AMBA, PESIN and MP2346 (3.0±0.4, 2.7±
0.5, 2.3±0.5 and 2.1±0.9%ID/g, respectively), but very low
for MP2653 (0.9±0.2%ID/g). In addition, MP2346 showed
undesirably high uptake in the kidneys (7.9±1.9%ID/g)
being significantly less for the other analogues. AMBA,
MP2346 and PESIN revealed favourable increases in
tumour to blood ratios over time while changes in tumour
to kidney and pancreas ratios for Demobesin-1 from 1 to
24 h after injection were significantly better than for the
other analogues. All analogues visualised PC-3 tumours by
SPECT/CT and autoradiography.
Conclusion In the present study the BN antagonist
Demobesin-1 was the best performing analogue showing
superior in vivo stability, highest tumour uptake and
retention while pancreatic and renal clearance were rapid.
PESIN and AMBAwere the best GRP agonists with sufficient
in vivo stabilities as well as high tumour uptake and retention.
Based on these results all three analogues deserve further
evaluation for clinical use in PC patients.
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Introduction
Prostate cancer (PC) is the most frequently diagnosed
cancer among men in the Western world. It is the third most
common cause of death [1]. After its introduction as a
biomarker, the prostate-specific antigen (PSA) has been
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increasingly used to detect PC [2] despite its limited
diagnostic specificity and prognostic value [3]. The
European Randomized Study of Screening for PC (ERSPC)
has shown that screening for PC using PSA detection and
digital rectal examination has resulted in a fourfold increase
in the detection of PC [4]. To select an optimal therapeutic
strategy for PC at the time of diagnosis, it is essential to
discriminate between organ-confined disease (with local
therapy such as surgery or radiation therapy still likely to be
beneficial) and PC beyond the confines of the gland (for
which a systemic approach such as hormonal therapy is the
first choice of treatment). Yet none of the standard imaging
modalities are sufficiently reliable in determining the extent
of minimal disease at the time of diagnosis [5, 6]. New non-
invasive sensitive imaging strategies to accurately diagnose,
stage and monitor PC are therefore required. Radiolabelled
peptide-based imaging by scintigraphy—single positron
emission tomography (SPECT) or positron emission
tomography (PET)—may be an interesting alternative to
fill this gap and improve diagnostic accuracy for early PC.
Gastrin-releasing peptide receptors (GRPRs) are overex-
pressed in several primary human tumours and metastases
[7]. Using tumour autoradiography, Markwalder and Reubi
[8] reported that GRPRs are expressed in invasive prostate
carcinomas and in prostatic intraepithelial neoplasms at
high density, whereas normal prostate tissue and hyperplas-
tic prostate tissue were predominantly GRPR negative.
These findings suggest that GRPR may be used as a
molecular basis for diagnosing and staging PC, similar to
somatostatin receptors (SST) which are being successfully
used in clinical practice [9–12].
Bombesin (BN) and its mammalian counterpart,
gastrin-releasing peptide (GRP), bind to the GRPR and
are involved in the regulation of a large number of
biological processes. Four subtypes of the bombesin
receptor are known of which the neuromedin B receptor
(BB1), GRPR (BB2) and BN receptor subtype 3 (BRS-3 or
BB3) are mammalian receptors and the fourth subtype
(BB4) is found in amphibians only [7]. The carboxyl-
terminal decapeptide of GRP is similar to that of the
14-amino acid amphibian BN peptide. BN possesses the
same biological and immunological activities and also has
a high affinity for GRPR. Since BN is assumed to be more
stable than GRP, developments have mainly been focused
on BN analogues. BN peptides have been coupled to
suitable chelators such as diethylenetriaminepentaacetic
acid (DTPA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′
″-tetraacetic acid (DOTA) and acyclic tetraamine (N4,
1,4,8,11-tetraazaundecane functionalised at position 6 for
binding to primary amine groups of peptides) to allow
labelling with various radionuclides.
DOTA- and DTPA-coupled BN analogues enable high
specific labelling with 111In because of the superior cellular
retention characteristics of this radionuclide [13]. The
DOTA chelator can also be labelled with therapeutic
radionuclides such as 90Y, 213Bi and 177Lu, offering the
possibility of using these BN analogues for therapeutic
purposes. Additionally, replacement of the DTPA chelator
with DOTA allows for radiolabelling with 68Ga, making
these peptides also suitable for PET imaging [14]. On the
other hand, Demobesin-1 with its N4 chelator enables
labelling with 99mTc, the most widely used radionuclide in
nuclear medicine diagnosis.
The suitability of several radiolabelled BN analogues for
PC targeting has been tested in preclinical and clinical
studies (for review see [15]). However, a valid comparison
of the potentials of the radiolabelled BN analogues
described in the literature is considerably limited due to
different evaluation protocols followed in individual pre-
clinical studies. This situation strongly hampers the
selection of the most suitable analogues for further clinical
validation. Using GRPR-overexpressing human PC-3
tumour-bearing SCID mice, we evaluated the PC targeting
efficacy of five promising radiolabelled BN analogues for
SPECT imaging under identical experimental conditions.
With the BN agonists PESIN, AMBA, MP2346 and
MP2653 and one antagonist Demobesin-1 [16–20] we
performed in vivo stability studies, biodistribution,
SPECT/CT imaging and ex vivo autoradiography along
with haematoxylin and eosin (H&E) staining.
Materials and methods
Analogues and radiolabelling
The tested analogues were selected on the basis of their
good PC targeting efficacy, as previously reported. In Fig. 1
I the amino acid compositions of BN and analogues studied
are shown. AMBA [18] and PESIN [20] were kindly
provided by Prof. Dr. Mäcke, University Hospital Basel,
Switzerland. MP2346 [16] and MP2653 [17] were supplied
by BioSynthema (St. Louis, MO, USA). In this study
radiolabelling of PESIN, AMBA, MP2346 and MP2653
was performed with 111InCl3 (Covedien, Petten, The
Netherlands), as described earlier [16, 21–23]. Incubation
for the DOTA peptides was performed at 80°C for 20 min.
Demobesin-1 was a gift from Dr. T. Maina and Dr. B.
Nock, Demokritos, Athens, Greece. This peptide was
radiolabelled with 99mTc as previously described by Nock
et al. [19, 23].
In order to prevent oxidation and radiolysis quenchers
were added to all radiolabelled analogues. Quenchers used
were ascorbate (Bufa BV, Uitgeest, The Netherlands),
gentisic acid (Covedien, Petten, The Netherlands) and
methionine (Fluka Biochemika, Buchs, Switzerland) [23].
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Quality control
The radiolabelling yield and radiochemical purity (RCP) of
the labelled analogues were assessed by instant thin-layer
chromatography (ITLC) in a 1:1 methanol:ammonium
acetate solution [19] and by HPLC (see below). For the
99mTc-labelled analogue Demobesin-1, an extra ITLC with
a 100% acetone solution was performed to quantify
99mTcO2 content. After radiolabelling and cooling down to
ambient temperature, 10 μl 4 mM DTPA was added to the
111In-DOTA peptides in order to avoid false-positive
quality control results, e.g. due to colloid formation to
complex any free 111In [24, 25]. For the yield of
incorporation of radioactivity a lower limit of 95% was set.
HPLC analysis of radiolabelled analogues was performed
on a Waters Breeze HPLC system (Waters, Etten-Leur, The
Netherlands) based on a 1525 binary HPLC pump connected
to a Unispec MCA gamma detector (Canberra, Zellik,
Belgium). A Symmetry C18 column (5 µm, 4.6 mm×
250 mm, Waters, Etten-Leur, The Netherlands) served as
stationary phase eluted with a solvent system consisting of
0.1% trifluoroacetic acid (TFA) in H2O (solvent A) and 0.1%
Fig. 1 I Amino acid sequence of native BN (14 amino acids) and the
BN analogues used in this study. Chelators: N4=6-R-1,4,8,11-
tetraazaundecane, DOTA=1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid, DTPA = diethylene triamine pentaacetic acid. Linkers:
R = BzDig = p-aminobenzyldiglycolic acid, PEG = polyethylene glycol.
Introduced amino acids: ACMpip =4-amino-carboxymethylpiperidine
(non-natural amino acid), Tha =β-(2-thienyl)-alanine (non-natural amino
acid), β-Ala = β-alanine (non-natural amino acid), Nle = norleucine,
Pro = proline, Tyr = tyrosine, Phe = phenylalanine, *reference number
from list references. II HPLC of all five radiolabelled analogues 1 h after
labelling
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TFA in methanol (solvent B) in a gradient protocol; 0–
2 min 100% solvent A (flow rate 1 ml/min), 2–3 min
55% solvent B, 3–30 min 65% solvent B (flow rate
0.5 ml/min), 30–38 min 100% solvent B (flow rate 1 ml/
min), 38–40 min 100% solvent B and 40–46 min 100%
solvent A.
RCP was estimated for each analogue by evaluating
radioactivity peaks eluted from the HPLC column and
calculating the area under the curve.
Cell culture
Human PC-3 cells were cultured in RPMI (Lonza,
Verviers, Belgium) supplemented with 5% fetal calf
serum (FCS) (GIBCO Invitrogen Co., Grand Island,
NY, USA) and 5 ml/500 ml penicillin/streptomycin
antibiotics (10,000 IU/ml penicillin, 10,000 IU/ml strep-
tomycin; Lonza, Verviers, Belgium). Cells were grown in
T175 Cellstar tissue culture flasks (Greiner Bio-One
GmbH, Frickenhausen, Germany) at 37°C in a humidi-
fied atmosphere containing 5% CO2. Cells were passaged
using a trypsin-ethylenediaminetetraacetic acid (EDTA)
solution (Lonza, Verviers, Belgium), 170,000 IU/l trypsin-
versene and 200 mg/l EDTA. For the present study, cells
were grown to near confluency and were than harvested
and counted. Suspensions of cells were dissolved in
phosphate-buffered saline (PBS) to yield approximately
6×106 cells/0.15 ml for subcutaneous injection.
PC-3 xenograft
Six- to seven-week-old male Swiss nu/nu mice (Charles
River, Kißlegg, Germany) were inoculated subcutaneously
with PC-3 cells in the right shoulder. A maximum of four
mice per cage were kept in 14×13×33.2 cm3 individually
ventilated cages (Techniplast), on sawdust (Woody-Clean,
type BK8/15; BMI) under a 12-h light-dark cycle, at 50±
5% relative humidity and controlled temperature (∼22°C).
Mice received irradiated chow and acidified drinking water
ad libitum. Experiments were initiated when the tumour
size reached a volume of 200–500 mm3 (3–5 weeks after
inoculation).
The experiment was approved by the Animal Experi-
mental Committee (DEC) of the Erasmus MC and
performed in agreement with The Netherlands Experiments
on Animals Act (1977) and the European Convention for
Protection of Vertebrate Animals Used for Experimental
Purposes (Strasbourg, 18 March 1986).
Peptide stability in vivo
Non-tumour-bearing 6- to 7-week-old male Swiss nu/nu
mice (Charles River, Kißlegg, Germany) were injected
intravenously into a lateral tail vein with 1 nmol radio-
labelled analogue labelled with 30 MBq 111In or 60 MBq
99mTc in a volume of 100 μl. Animals were sacrificed at 5
and 15 min after administration. For each time point two
animals were used.
Blood was collected by orbital puncture in an EDTA
tube to prevent clotting and put on ice. Subsequently,
samples were centrifuged for 5 min, 9,500 g at +4°C, after
which the supernatant was collected and precipitated with
ethanol (serum:ethanol 1:1). At HPLC run the final ethanol
concentration was below 50%. Precipitated serum was then
centrifuged for 5 min at 9,500 g to dispose of large
proteins. The supernatant containing the radiolabelled
peptide was used for HPLC analysis. Results were
indicated as percentage of intact radiolabelled peptide as
determined from the HPLC analysis (% intact peptide of
two mice per time point).
Biodistribution studies
PC tumour-bearing mice were injected intravenously into a
lateral tail vein with 10 pmol of analogue labelled with an
activity of 0.5 MBq 111In or 2.5 MBq 99mTc, in a volume of
0.1 ml. Animals were sacrificed at 1, 4 or 24 h after
administration of test analogue. For each time point four
animals were used. To discriminate between receptor-
specific and non-specific binding, for each analogue three
additional mice were co-injected with an excess of
unlabelled [Tyr4]BN (0.1 mg in 0.1 ml) and sacrificed 4 h
post-injection (p.i.). The tumours and selected tissues
(blood, pancreas, kidney and colon) were excised, weighed
and counted for radioactivity in a gamma counter (LKB-
1282-Compugamma system, PerkinElmer, Groningen, The
Netherlands). Data were calculated as percentage of the
injected dose per gram of tissue (%ID/g) using counts from
0.01 ml of the original injectate as reference.
SPECT/CT
SPECT/CT scans were performed with a four-head multi-
plexing multi-pinhole NanoSPECT/CT™ (Bioscan Inc.,
Washington DC, USA). Each head was equipped with an
application-specific tungsten-based collimator with nine
pinholes of 1.4 mm diameter imaging a cylindrical field
of view, providing a reconstructed resolution in the
submillimetre range. For SPECT/CT a peptide amount of
0.25 nmol in 0.1 ml was injected intravenously. This is
needed to enlarge peptide amount for tumour binding to
achieve sufficient radioactivity for imaging. Total injected
activities ranged from 23–31 MBq for the 111In analogues
to 142 MBq for Demobesin-1. For each analogue, whole-
body scans were performed at 1 and 4 h after injection of the
radiolabelled analogue. An acquisition time of approximately
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200 s per view was used, resulting in a total scanning time of
about 1 h 30min per animal. CT scans were performed with
the integrated CT using a tube voltage of 45 kV and an
exposure time of 1,500 ms per view. After acquisition,
the SPECT data were reconstructed with HiSPECT
software (Scivis GmbH, Göttingen, Germany). For CT
reconstruction a cone beam filtered backprojection was
employed. SPECT and CT data were automatically
coregistered since both modalities shared the same axis
of rotation. The fused data sets were analysed in the
InVivoScope post-processing software (Bioscan Inc.,
Washington DC, USA). Mice were sacrificed and their
tumours were dissected and quickly frozen in liquid
nitrogen for subsequent ex vivo autoradiography.
Ex vivo autoradiography
Frozen PC-3 tumours derived from SPECT animals were cut
into sections of 10 µm (Microm Cryo-Star HM 560 M,
Walldorf, Germany) and mounted on glass slides (Superfrost
plus slides, Menzelgläser, Braunschweig, Germany). Tumour
sections were exposed to Super Resolution phosphor imaging
screens (Packard Instruments Co., Meriden, CT, USA) in
X-ray cassettes. After 24–72 h screens were imaged by a
Cyclone phosphor imager and analysed using the OptiQuant
03.00 image processing system (PerkinElmer, Groningen,
The Netherlands). After exposure, PC-3 sections were stained
with H&E and the staining pattern was compared to the
corresponding autoradiogram.
Statistics
Statistical analyses were performed using SPSS 11.01
(SPSS Inc., Chicago, IL, USA). For this study we applied
the Mann-Whitney U test. Statistical significance was
assumed if p values were lower than 0.05.
Results
Quality control
HPLC radiochromatograms for all analogues are presented
in Fig. 1 II. Analyses of ITLC (data not shown) and HPLC
indicated a labelling yield for all analogues of more than
97%. For Demobesin-1, formation of 99mTcO2 colloid was
<1% as concluded from ITLC analysis. RCP ranged from
74 to 93% for the various peptides.
Peptide stability in vivo
Peptide stability in vivo was highest for Demobesin-1 for
both time points. At 5 min p.i. 64.1±1.6% was still intact
followed by AMBA (36.1±2.7%), PESIN (23.3±1.4%),
MP2346 (21.2±0.8%) and MP2653 (9.8±0.5%). At 15 min
p.i. still 41.03±0.11% of intact Demobesin-1 could be
recovered with lower recoveries for AMBA (9.8±1.1%),
MP2346 (3.4±1.3%), MP2653 (2.8±0.4%) and PESIN
(1.8±0.6%) (Table 1). As derived from dose calibrator
measurements of activities in supernatant and serum it
could be concluded that over 90% of total activity had been
extracted from the serum after the precipitation procedure
(data not shown).
Biodistribution studies
Uptake results in various tissues for all radiolabelled
analogues at all time points are summarised in Table 2.
Figure 2 shows a graph of the tumour uptake results for all
analogues at all time points. The highest PC-3 tumour
uptake was obtained with Demobesin-1 (3.0±0.4%ID/g) at
1 h p.i. The analogues AMBA, PESIN, MP2346, and
MP2653 showed lower tumour uptakes at this time point:
2.7±0.5, 2.3±0.5, 2.1±0.9 and 0.9±0.2%ID/g, respectively.
The differences in tumour uptake at 4 h p.i. were consistent
with those at 1 h. At 24 h, tumour retention of the 111In-DOTA
analogues AMBA and PESIN was highest: 1.6±0.4 and
1.2±0.2%ID/g, respectively, with lower outcomes for
MP2346, Demobesin-1 and MP2653 (0.7±0.4, 0.4±0.1 and
0.4±0.1%ID/g, respectively). 99mTc-labelled Demobesin-1
showed the most substantial decline in tumour uptake of
7.1-fold from 1 to 24 h, unlike what was observed for the
other peptides. Tumour uptake of MP2653 was significantly
lower than that of the other analogues at all time points.
AMBA showed the highest uptake in the GRPR-
expressing pancreas at 1 h p.i. (40.9±3.3%ID/g). Lower
uptake was found for Demobesin-1, PESIN, MP2653 and
MP2346 (23.8±3.2, 20.8±3.9, 14.7±3.8 and 9.0±2.5%ID/g,
respectively). Demobesin-1 showed a considerable washout
from pancreas resulting in a 25-fold increase in tumour to
pancreas ratio from 1 to 24 h p.i. Increase in the tumour to
pancreas ratio over time was significantly less for MP2653,
PESIN, AMBA and MP2346: 2.7-, 1.0-, 0.7- and 0.5-fold,
respectively (Fig. 3a).
In addition to the pancreas, also GRPR-specific uptake
of radiolabel in colon was observed. Receptor specificity
of peptide uptake was confirmed by co-injecting an
excess of unlabelled [Tyr4]BN resulting in strongly
reduced uptake (>80%) of radiolabel in the colon. PC-3
tumours and GRPR-expressing pancreas showed a com-
parable blocking pattern for all analogues indicating
GRPR-specific uptake. Colon uptake was highest for
AMBA as compared to other analogues at all time points:
6.8±0.9 versus 2.9±1.5, 2.5±1.2, 2.5±0.4 and 2.1±0.4%
ID/g at 1 h p.i. for PESIN, Demobesin-1, MP2653 and
MP2346, respectively (Table 1).
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The uptake of radiolabel by the kidneys was significantly
higher for MP2346 (7.9±1.9%ID/g at 1 h) as compared to the
other analogues at all time points: 3.6±0.7, 3.2±1.2, 2.7±1.0
and 2.0±0.3%ID/g at 1 h for AMBA, Demobesin-1, PESIN
andMP2653, respectively (Table 1). The change in tumour to
kidney ratio from 1 to 24 h p.i. was significantly higher for
Demobesin-1 as compared to the other analogues: 3.6-fold
versus 2.1-, 1.8-, 1.8- and 1.0-fold for PESIN, AMBA,
MP2653 and MP2346, respectively (Fig. 3b).
All peptides, except for MP2653 and Demobesin-1,
showed high tumour to blood ratios indicating fast
clearance from circulation. PESIN showed the largest
increase in tumour to blood ratio of 14.4-fold from 1 to
4 h followed by MP2346 and AMBA (5.7 and 5.5,
respectively) with the lowest ratios for MP2653 and
Demobesin-1 (3.5 and 2.6, respectively) (Fig. 3c).
SPECT/CT and ex vivo autoradiography
All analogues were able to image subcutaneous PC-3
tumours by SPECT/CT at 1 and 4 h p.i. (Fig. 4 I).
Additionally, ex vivo autoradiography of PC-3 tumours
was performed at 1 and 4 h p.i. Autoradiography revealed
considerable heterogeneity of peptide binding within the
tumour for all analogues with reduced binding in some
(central) areas of the tumour as was also observed by in
vivo SPECT/CT imaging. H&E staining of consecutive
slides revealed that this heterogeneous expression pattern
coincided with reduced cell density in these tumour areas
(Fig. 4 II).
Discussion
In order to initiate BN-based scintigraphic (SPECT) patient
studies for the imaging of early PC, we reviewed preclinical
studies from the literature as well as our own studies in
search of a promising BN analogue. Due to the lack of
standardisation of experiments performed by various
research groups, finding consistent comparisons—and thus
a reliable choice of candidates—for further clinical valida-
tion was very difficult. For this reason, we decided to set up
Organ [111In]MP2653 [111In]MP2346 [111In]PESIN [111In]AMBA [99mTc]Demobesin-1
A. 1 h p.i. (%ID/g ± SD)
Blood 0.2±0.1 0.4±0.5 0.3±0.1 0.2±0.0 0.6±0.1
Pancreas 14.7±3.8 9.0±2.5 20.8±3.9 40.9±3.3 23.8±3.2
Kidneys 2.0±0.3 7.9±1.9 2.7±1.0 3.6±0.7 3.2±1.2
Colon 2.5±0.4 2.1±0.4 2.9±1.5 6.8±0.9 2.5±1.2
Tumour 0.9±0.2 2.1±0.9 2.3±0.5 2.7±0.5 3.0±0.4
B. 4 h p.i. (%ID/g ± SD)
Blood 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.0
Pancreas 11.4±2.5 8.9±2.1 17.5±2.8 40.5±7.6 4.1±1.6
Kidneys 1.2±0.4 10.6±1.6 1.5±0.4 3.4±1.4 1.1±0.2
Colon 1.6±0.6 1.8±0.7 3.6±0.4 5.6±1.2 1.2±0.3
Tumour 0.7±0.2 1.4±0.4 1.6±0.2 1.9±0.3 2.2±0.4
C. 24 h p.i. (%ID/g ± SD)
Blood 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Pancreas 2.4±0.7 5.8±1.4 14.5±2.8 32.9±5.2 0.1±0.0
Kidneys 0.6±0.3 2.8±0.9 0.7±0.4 1.3±0.5 0.1±0.0
Colon 0.8±0.2 0.6±0.3 1.0±0.4 3.2±0.8 0.1±0.1
Tumour 0.4±0.1 0.7±0.4 1.2±0.2 1.6±0.4 0.4±0.1
Table 2 Biodistribution data of
all five radiolabelled analogues
at time points A, B and C in
PC-3 tumour-bearing athymic
nude mice injected with 10 pmol
peptide, labelled with an activity
of 0.5 MBq 111In or 2.5 MBq
99mTc, in a volume of 0.1 ml
into a lateral tail vein. Results
are the mean and standard
deviation of four mice per
analogue per time point
Mean (5 min) Mean (15 min)
Analogue Mouse 1 Mouse 2 Mouse 1 Mouse 2
[99mTc]Demobesin-1 62.9 65.2 41,0 41.1
[111In]AMBA 34.2 38.0 9,0 10.6
[111In]PESIN 24.4 22.4 1.4 2.3
[111In]MP2346 21,8 20.6 4.3 2.4
[111In]MP2653 10.2 9.5 2.6 3.1
Table 1 In vivo stability of all
analogues at 5 and 15 min p.i.
injecting 1 nmol of radiolabelled
analogue (30 MBq 111In or 60
MBq 99mTc) i.v. in a volume of
0.1 ml in non-tumour-bearing
nude mice. Results are indicated
as % intact analogue from total
injected analogue per mouse
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a comparative study using a number of BN analogues under
identical experimental conditions. Five radiolabelled ana-
logues that had already been shown to have good GRPR
affinities and targeting characteristics were selected for this
study. Four of the radiolabelled BN analogues were GRPR
agonists (AMBA, PESIN, MP2653 and MP2346) and one
was an antagonist (Demobesin-1) [16–20].
The choice for the BN agonist PESIN was based on
studies that reported PC-3 tumour uptake of PESIN labelled
with 67Ga of 14.8%ID/g 1 h after injection [20]. In another
study, PC-3 tumour uptake of AMBA labelled with 177Lu at
1 h p.i. was 6.4%ID/g [18]. This analogue has already been
applied in a therapeutic clinical study [26]. MP2346 [16]
and MP2653 [17] labelled with 111In have also shown high
affinity for GRPR. All agonists were labelled with 111In via
DTPA or DOTA.
The antagonist Demobesin-1 was included because of its
very good profile (tumour uptake 1 h p.i. of 16.2%ID/g in
PC-3 tumour-bearing mice) shown in a preclinical study by
Nock et al. [19]. Furthermore, recent preclinical studies
using SST analogues suggest that radiolabelled antagonists
are superior to agonists with regard to tumour uptake and
retention of radioactivity [27]. Although it was shown that
the antagonists did not trigger receptor internalisation in SST
receptor-expressing cells—a feature that was previously
thought to be a crucial characteristic for good retention of
Fig. 2 Tumour uptake for all analogues in PC-3 tumour-bearing
athymic nude mice injected with 0.5 MBq 111In or 2.5 MBq 99mTc
bound to 10 pmol of peptide conjugate, in a volume of 0.1 ml into a
lateral tail vein sacrificed at 1, 4 and 24 h p.i. Results are indicated as
mean ± standard deviation of four mice per analogue per time point
Fig. 3 Ratios calculated from biodistribution in PC-3 tumour-bearing
athymic nude mice injected with 0.5 MBq 111In or 2.5 MBq 99mTc
bound to 10 pmol of peptide conjugate, in a volume of 0.1 ml into a
lateral tail vein sacrificed at 1, 4 and 24 h p.i. Data show the tumour to
blood ratio (a), tumour to pancreas ratio (b) and tumour to kidney
ratio (c) at all time points for all radiolabelled analogues
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tumour radioactivity—tumour values were reported to be
higher for the antagonist than for the agonist. Also, the
antagonists were shownwashed out from normal organsmuch
faster than agonists, which would potentially result in a
reduction in radiotoxicity of normal organs. Recently, GRPR-
based PC-3 tumour targeting using Demobesin-1 was also
shown to be superior to an agonistic BN analogue with
comparable receptor affinity [28].
The differences in half-life between the radionuclides we
used required the inclusion of both early and late evaluation
time points (1, 4 and 24 h p.i.). This enabled us to evaluate
tissue and blood retention rates of the analogues over time.
In the biodistribution studies we used 10 pmol of peptide
per animal for all analogues. The peptide mass selected was
based on the amounts reported in the literature [19, 20].
Also it was chosen while the peptide mass enables an
appropriate labelling yield for biodistribution for all
analogues [19, 20].
In the present study Demobesin-1 showed the highest
tumour uptake at 1 and 4 h p.i., although these values were
not statistically significantly different from those of
AMBA, PESIN and MP2346. Tumour uptake of MP2653
was significantly lower when compared with that of all
other analogues at all time points. Since sufficient tumour
Fig. 4 I SPECT/CT image of
the PC-3 tumour in athymic
xenografts at 1 h after i.v. tail
injection of 0.25 nmol of radio-
labelled analogue (23–31 MBq
for 111In and 142 MBq for
99mTc) in a volume of 0.1 ml
into a lateral tail vein. a AMBA,
b Demobesin-1, c MP2653, d
PESIN, e MP2346. II Autora-
diograms (right) and
corresponding H&E-stained
sections (left) of a PC-3 tumour
derived from a mouse 4 h after
injection of MP2346 (a) and
AMBA (b). Ex vivo tumour
sections were derived from PC-3
tumour-bearing athymic nude
mice injected with 0.25 pmol
peptide, labelled with 23–
31 MBq for 111In analogues in a
volume of 0.1 ml into a lateral
tail vein
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uptake is a prerequisite for diagnostic and therapeutic use,
MP2653 was excluded from further evaluation. Although
MP2346 showed good tumour uptake, it had an unfavourable
and significantly higher uptake in the kidney when compared
with the other analogues at all time points. This high renal
uptake strongly limits its clinical use because of potential
nephrotoxicity during peptide radionuclide receptor therapy
(PRRT). For this reason, MP2346 was not further considered
as best clinical analogue.
In contrast to the reduction in tumour uptake of
Demobesin-1 from 3.0±0.4%ID/g at 1 h to 0.4±0.1%ID/g
at 24 h p.i., tumour retention of radioactivity after AMBA
and PESIN injection remained fairly stable over this time
period, indicating that these two analogues have potential
for imaging at later time points. Also, this characteristic
may be well suited for PRRT when BN analogues are
coupled to therapeutic radionuclides for PRRT. Since a
DOTA chelator allows AMBA and PESIN to bind a wide
variety of radionuclides, both conjugates are suitable for
imaging and PRRT purposes. Research on labelling N4-
chelated analogues with the beta-emitting 188Re is ongoing.
The pancreas is the organ with the highest GRPR
expression in mice. Its (non-intended) peptide uptake in
relation to the targeted tumour uptake is of concern when
evaluating GRPR targeted peptides. The tumour to pancreas
ratio of Demobesin-1 showed an impressive and significant
4.6-fold increase from 1 to 4 h, which was much less
marked in the other analogues (0.7-fold in AMBA and 1.2-
fold in PESIN). In accordance with the study of Cescato et
al. [28], the BN antagonist Demobesin-1 was rapidly
washed out from the GRPR-expressing pancreas, while
tumour uptake remained relatively high resulting in 25-fold
higher tumour to pancreas ratios. We also observed this
phenomenon in a patient study where we administered
Demobesin-1 and compared it with an agonist 111In-[DTPA-
Pro1,Tyr4]bombesin (unpublished data).
Besides uptake of radioactivity in the pancreas, GRPR-
specific uptake—as could be concluded from in blocking
data—by the colon was also observed. Colon uptake is also
highly relevant to PC imaging as it may interfere with detection
of PC metastatic lesions at abdominal sites. Furthermore, it
may induce colon radiotoxicity when employed for PRRT.
Unfavourable GRPR-specific colon uptake was twofold higher
for AMBA than for the other peptides.
Ideally, the tumour to blood ratios of analogues should
increase over time with high retention in the tumour and
declining activity in the circulation. Both AMBA and
PESIN analogues showed large increases in tumour to
blood ratios from 1 to 4 h (5.5-fold and 14.1-fold,
respectively). In contrast, Demobesin-1 showed the smallest
change in this ratio (a 2.7-fold change between 1 and 4 h).
The slower clearance of Demobesin-1 from the blood
resulting in a lower tumour to blood ratio in comparison
with the DOTA-chelated peptides may be related to the fact
that the agonists are more hydrophilic and are therefore
rapidly cleared by the kidney, whereas the lipophilic
Demobesin-1 is excreted by the hepatobiliary tract as well.
This could influence clearance kinetics. Rapid conversion to
hydrophilic metabolites may also accelerate blood clearance
of the agonists. Despite its favourable high tumour to blood
ratio, the very high renal uptake of MP2346 remains a major
disadvantage of this peptide.
Generally, peptides for use in peptide receptor targeted
scintigraphy or therapy are chosen for their good BN
receptor-targeting characteristics and in vitro stability. The
in vitro serum half-life data of the BN peptides used in this
study ranged from 3 h to several days [17–19, 21]. Peptide
stability of analogues in vivo is, however, of much more
relevance. For this reason, in the present study we
determined the in vivo peptide stability of all analogues
using HPLC. Peptide stability in vivo of all four agonists
was very similar. Demobesin-1 was the most stable
analogue. We can however not completely exclude the
presence of unknown radiolabelled metabolites besides
the intact peptide in the main peaks from HPLC. Despite
the significantly longer in vivo peptide stability of
Demobesin-1, tumour uptakes for this analogue were not
significantly different from those of AMBA and PESIN.
This implies that interactions between GRPR and BN occur
rapidly. There was no direct correlation between in vivo
peptide stability and analogue performance in mice.
The administration of pharmacologically active agonistic
peptides is known to cause endocrine and haemodynamic
effects by the process of endocytosis [29]. Antagonists on
the other hand do not have the potential to enter and
activate cells and, as a consequence, pharmacological side
effects may be less. This is especially relevant for PRRT
where higher amounts of peptide are used than for imaging
studies. Furthermore, several experimental studies have
shown that BN antagonists induce anti-tumour effects [30–
34], while BN agonists generally stimulate PC tumour
growth [7, 35, 36]. Another advantage of Demobesin-1 is
that it is highly selective for GRPR and has no affinity for
other BN receptor subtypes, NMB-R and BB3-R [19]. The
agonists AMBA and PESIN are not selective and bind to
both GRPR and NMB-R [18, 20].
With regard to absolute tumour uptake of radioactivity,
the present study showed lower tissue uptakes than is
described for these analogues in the literature. The variation
in radionuclides, amounts of peptide, mouse strain (species,
sex, weight), PC-3 tumour cells (passage number, culture
conditions) used, tumour size and vascularisation of the
tumour may all be factors that determine uptake of
radioactivity resulting in variable outcomes. This further
underlines the necessity to evaluate and compare such
analogues under standardised conditions.
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The present study showed that all analogues were able to
target subcutaneous PC-3 tumours as visualised by SPECT/
CT. Ex vivo autoradiography of PC-3 tumours further
revealed that in all analogues there was considerable
heterogeneity in the distribution of radioactivity between
individual tumours. The heterogenic pattern could be
histologically related to areas with reduced cell density,
predominantly in the centre of the tumours. This was
further supported by the SPECT/CT images showing a rim-
like tumour image. When considering using radiolabelled
BN for PRRT, it should be taken into account that the area
that will be irradiated contains all vital PC cells. Mouse
models are not ideal while central necrosis results in
underestimation of uptake (%ID/g). This underlines the
necessity to perform biodistribution on mice with small
tumours only. Furthermore, it should be investigated
whether central necrosis occurs in patient tumours as well.
In conclusion, the comparison of five analogues per-
formed in the present study provides a realistic reflection of
the potential of a number of peptides, in spite of the
differences between tumour uptake and normal organ
values found in our experiments and those of previous
studies. The BN antagonist Demobesin-1 showed the
highest tumour uptake 1 and 4 h p.i., with a particularly
good tumour to pancreas ratio and a significantly higher in
vivo analogue stability compared with the other analogues.
This good performance, in combination with the advantages
of the use of antagonists over agonists and its 99mTc label,
make Demobesin-1 a very attractive analogue for PC
imaging. Based on high tumour uptake, retention profiles
and good tumour to blood ratios combined with sufficient
stability in vivo, PESIN and AMBA outperformed the other
two agonists. As they have a DOTA chelator, both
analogues are currently more easily applicable for PRRT
than the N4–functionalised Demobesin-1 analogue. Our
results indicate that all three BN analogues deserve further
evaluation for clinical nuclear imaging, and possibly PRRT,
of human PC. Demobesin-1 has been selected for a first
proof of concept clinical study.
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